Literature DB >> 29581546

Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria.

Eli Muchtar1, Angela Dispenzieri1, Nelson Leung1,2, Martha Q Lacy1, Francis K Buadi1, David Dingli1, Martha Grogan3, Suzanne R Hayman1, Prashant Kapoor1, Yi Lisa Hwa1, Amie Fonder1, Miriam Hobbs1, Rajshekhar Chakraborty1,4, Wilson Gonsalves1, Taxiarchis V Kourelis1, Rahma Warsame1, Stephen Russell1, John A Lust1, Yi Lin1, Ronald S Go1, Steven Zeldenrust1, Robert A Kyle1, S Vincent Rajkumar1, Shaji K Kumar1, Morie A Gertz5.   

Abstract

Organ recovery following anti-plasma cell therapy is associated with improved outcome in patients with AL amyloidosis. Current organ response criteria do not consider the depth of response. Newly diagnosed AL amyloidosis patients who had involvement of at least one evaluable organ and documentation of organ response were included. Cardiac response was seen in 182 patients. Time to cardiac response was 9.4 months. Renal response was seen in 278 patients, at a median time to response of 6 months. Hepatic response was seen in 70 patients, with a median time to response of 6.1 months. In all organs, the deeper the organ response achieved, the longer the survival. This led to four organ response criteria: complete organ response (nadir NT-proBNP ≤400 pg/mL; nadir proteinuria ≤200 mg per 24 h; nadir alkaline phosphatase ≤×2 lower limit of normal); very good partial organ response (>60% reduction in parameter not meeting complete organ response definition); partial organ response (31-60% reduction in parameter); and non-responder (≤30% reduction in organ response parameter). Cardiac and renal progression were associated with baseline organ impairment and inversely associated with the depth of organ response. Grading the depth of organ response provides additional valuable prognostic information for newly diagnosed AL amyloidosis patients.

Entities:  

Mesh:

Year:  2018        PMID: 29581546     DOI: 10.1038/s41375-018-0060-x

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  17 in total

1.  When should treatment of AL amyloidosis start at relapse? Early, to prevent organ progression.

Authors:  Giovanni Palladini; Giampaolo Merlini
Journal:  Blood Adv       Date:  2019-01-22

Review 2.  New developments in diagnosis, risk assessment and management in systemic amyloidosis.

Authors:  Iuliana Vaxman; Angela Dispenzieri; Eli Muchtar; Morie Gertz
Journal:  Blood Rev       Date:  2019-11-02       Impact factor: 8.250

3.  Organ responses with daratumumab therapy in previously treated AL amyloidosis.

Authors:  Alfred Chung; Gregory P Kaufman; Surbhi Sidana; Erik Eckhert; Stanley L Schrier; Richard A Lafayette; Sally Arai; Ronald M Witteles; Michaela Liedtke
Journal:  Blood Adv       Date:  2020-02-11

Review 4.  Systemic amyloidosis: moving into the spotlight.

Authors:  Oliver C Cohen; Ashutosh D Wechalekar
Journal:  Leukemia       Date:  2020-04-09       Impact factor: 11.528

5.  Depth of response prior to autologous stem cell transplantation predicts survival in light chain amyloidosis.

Authors:  Iuliana Vaxman; M Hasib Sidiqi; Abdullah S Al Saleh; Shaji Kumar; Eli Muchtar; Angela Dispenzieri; Francis Buadi; David Dingli; Martha Lacy; Suzanne Hayman; Nelson Leung; Wilson Gonsalves; Taxiarchis Kourelis; Rahma Warsame; William Hogan; Morie Gertz
Journal:  Bone Marrow Transplant       Date:  2020-11-18       Impact factor: 5.483

6.  The utility of repeat kidney biopsy in systemic immunoglobulin light chain amyloidosis.

Authors:  Avital Angel-Korman; Aala Jaberi; Vaishali Sanchorawala; Andrea Havasi
Journal:  Amyloid       Date:  2019-10-09       Impact factor: 7.141

7.  Amyloidosis-the Diagnosis and Treatment of an Underdiagnosed Disease.

Authors:  Sandra Ihne; Caroline Morbach; Claudia Sommer; Andreas Geier; Stefan Knop; Stefan Störk
Journal:  Dtsch Arztebl Int       Date:  2020-03-06       Impact factor: 5.594

Review 8.  Amyloidosis in Heart Failure.

Authors:  Sandra Ihne; Caroline Morbach; Laura Obici; Giovanni Palladini; Stefan Störk
Journal:  Curr Heart Fail Rep       Date:  2019-12

9.  Characterization and prognostic implication of delayed complete response in AL amyloidosis.

Authors:  Eli Muchtar; Morie A Gertz; Shaji K Kumar; Martha Q Lacy; Nelson Leung; Francis K Buadi; David Dingli; Suzanne R Hayman; Ronald S Go; Prashant Kapoor; Wilson Gonsalves; Taxiarchis V Kourelis; Rahma Warsame; Yi Lisa Hwa; Amie Fonder; Miriam Hobbs; Stephen Russell; John A Lust; Mustaqueem Siddiqui; S Vincent Rajkumar; Robert A Kyle; Angela Dispenzieri
Journal:  Eur J Haematol       Date:  2020-12-04       Impact factor: 2.997

10.  Phase 1a/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis.

Authors:  Camille Vanessa Edwards; Nisha Rao; Divaya Bhutani; Markus Mapara; Jai Radhakrishnan; Sofia Shames; Mathew S Maurer; Siyang Leng; Alan Solomon; Suzanne Lentzsch; Andrew Eisenberger
Journal:  Blood       Date:  2021-12-23       Impact factor: 25.476

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.